John Joseph Johnston net worth and biography

John Johnston Biography and Net Worth

Director of MaxCyte

John Johnston has served on our Board since 2016. From 2011 until his retirement from his financial career in 2013, Mr. Johnston served as managing director of institutional sales at Nomura Code Securities, Ltd., a brokerage company, and from 2008 to 2011, he was director of sales and trading at the investment bank Seymour Pierce.

In 2003, Mr. Johnston founded Revera Asset Management, where he oversaw an investment trust, a unit trust and a hedge fund, which he ran until 2007. Mr. Johnston began his investment career at the Royal Bank of Scotland and previously held positions at investment firms Legg Mason Investors and Murray Johnstone. Within the past five years, Mr. Johnston served as a non-executive director of the publicly held company Midatech Pharma plc (now Biodexa Pharmaceuticals plc). Mr. Johnston received his BA in commerce from Abertay University and his MBA from the University of Dundee.

Our Board believes Mr. Johnston’s executive leadership and operational experience qualify him to serve as a director.

What is John Joseph Johnston's net worth?: The estimated net worth of John Joseph Johnston is at least $224.28 thousand as of January 27th, 2025. Johnston owns 141,950 shares of MaxCyte stock worth more than $224,281 as of December 5th. This net worth estimate does not reflect any other investments that Johnston may own. Learn More about John Joseph Johnston's net worth.
How do I contact John Joseph Johnston?: The corporate mailing address for Johnston and other MaxCyte executives is 22 FIRSTFIELD ROAD SUITE 110, GAITHERSBURG MD, 20878. MaxCyte can also be reached via phone at 301-944-1700 and via email at [email protected]. Learn More on John Joseph Johnston's contact information.
Has John Joseph Johnston been buying or selling shares of MaxCyte?: John Joseph Johnston has not been actively trading shares of MaxCyte over the course of the past ninety days. Most recently, John Joseph Johnston sold 3,000 shares of the business's stock in a transaction on Monday, January 27th. The shares were sold at an average price of $4.64, for a transaction totalling $13,920.00. Following the completion of the sale, the director now directly owns 141,950 shares of the company's stock, valued at $658,648. Learn More on John Joseph Johnston's trading history.
Who are MaxCyte's active insiders?: MaxCyte's insider roster includes Douglas Doerfler (Founder), Douglas Doerfler (Founder), Stanley Erck (Director), John Johnston (Director), Maher Masoud (CEO), David Sandoval (Senior Vice President and General Counsel), Ali Soleymannezhad (Insider), and Douglas Swirsky (CFO). Learn More on MaxCyte's active insiders.
Are insiders buying or selling shares of MaxCyte?: In the last year, MaxCyte insiders bought shares 5 times. They purchased a total of 355,000 shares worth more than $479,950.00. In the last year, insiders at the sold shares 7 times. They sold a total of 29,653 shares worth more than $95,594.74. The most recent insider tranaction occured on August, 13th when CFO Douglas J Swirsky bought 50,000 shares worth more than $64,500.00. Insiders at MaxCyte own 3.3% of the company. Learn More about insider trades at MaxCyte.
Information on this page was last updated on 8/13/2025.

John Joseph Johnston Insider Trading History at MaxCyte

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/27/2025	Sell	3,000	$4.64	$13,920.00	141,950
12/26/2024	Sell	3,000	$4.01	$12,030.00	141,950
10/28/2024	Sell	3,000	$3.72	$11,160.00	141,950
9/26/2024	Sell	3,000	$3.82	$11,460.00	141,950
8/26/2024	Sell	3,000	$4.28	$12,840.00	141,950
7/26/2024	Sell	3,000	$4.75	$14,250.00	141,950
6/27/2024	Sell	10,000	$3.99	$39,900.00	141,950
3/26/2024	Sell	5,000	$4.41	$22,050.00	120,583
1/26/2024	Sell	5,000	$5.12	$25,600.00	120,583
12/26/2023	Sell	5,000	$4.53	$22,650.00	120,583
11/27/2023	Sell	5,000	$4.59	$22,950.00	120,583
11/14/2023	Sell	10,000	$3.71	$37,100.00	120,583
8/30/2023	Sell	2,841	$3.70	$10,511.70	120,583
8/28/2023	Sell	100	$3.70	$370.00	120,583
7/26/2023	Sell	5,000	$4.75	$23,750.00	120,583
6/27/2023	Sell	7,471	$4.39	$32,797.69	120,583

John Joseph Johnston Buying and Selling Activity at MaxCyte

MaxCyte Company Overview

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

Today's Range

Now: $1.58

$1.50

$1.62

50 Day Range

MA: $1.62

$1.44

$1.83

2 Week Range

Now: $1.58

$1.26

$5.20

Volume

577,871 shs

Average Volume

856,912 shs

Market Capitalization

$168.54 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.22